974 Federal Register / Vol. 87, No. 5 / Friday, January 7, 2022 / Notices 

CONTESTING RECORD PROCEDURES: 

See § 4.13 of the FTC’s Rules of 

Practice, 16 CFR 4.13. For additional 

guidance, see also Appendix II (How to 

Make A Privacy Act Request), available 

on the FTC’s website at https://

www.ftc.gov/about-ftc/foia/foia-readingrooms/privacy-act-systems at 73 FR 

33592, 33634 (June 12, 2008). 

NOTIFICATION PROCEDURES: 

See § 4.13 of the FTC’s Rules of 

Practice, 16 CFR 4.13. For additional 

guidance, see also Appendix II (How to 

Make A Privacy Act Request), available 

on the FTC’s website at https://

www.ftc.gov/about-ftc/foia/foia-readingrooms/privacy-act-systems at 73 FR 

33592, 33634 (June 12, 2008). 

EXEMPTIONS PROMULGATED FOR THE SYSTEM: 

Records contained in this system that 

have been placed on the FTC public 

record are available upon request or, 

where applicable, made available 

online. See FTC–I–6 (Public Records— 

FTC). However, pursuant to 5 U.S.C. 

552a(k)(2), records in this system, which 

reflect records that are contained in 

other systems of records that are 

designated as exempt, are exempt from 

the requirements of subsections (c)(3), 

(d), (e)(1), (e)(4)(G), (H), (I), and (f) of 5 

U.S.C. 552a. See § 4.13(m) of the FTC 

Rules of Practice, 16 CFR 4.13(m). 

HISTORY: 

73 FR 33591–33634 (June 12, 2008). 

* * * * * 

Josephine Liu, 

Assistant General Counsel for Legal Counsel. 

[FR Doc. 2022–00075 Filed 1–6–22; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Toxic Substances and 

Disease Registry 

[30Day–22–22BJ] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Agency for 

Toxic Substances and Disease Registry 

(ATSDR) has submitted the information 

collection request titled Evaluating the 

Association between Serum 

Concentrations of Per- and 

Polyfluoroalkyl substances (PFAS) and 

Symptoms and Diagnoses of Selected 

Acute Viral Illnesses to the Office of 

Management and Budget (OMB) for 

review and approval. ATSDR previously 

published a ‘‘Proposed Data Collection 

Submitted for Public Comment and 

Recommendations’’ notice on April 5, 

2021 to obtain comments from the 

public and affected agencies. ATSDR 

did not receive comments related to the 

previous notice. This notice serves to 

allow an additional 30 days for public 

and affected agency comments. 

ATSDR will accept all comments for 

this proposed information collection 

project. The Office of Management and 

Budget is particularly interested in 

comments that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Evaluating the Association between 

Serum Concentrations of Per- and 

Polyfluoroalkyl Substances (PFAS) and 

Symptoms and Diagnoses of Selected 

Acute Viral Illnesses—New—Agency for 

Toxic Substances and Disease Registry 

(ATSDR). 

Background and Brief Description 

Per- and poly-fluoroalkyl substances 

(PFAS) are a large, diverse group of 

thousands of chemicals that have been 

used extensively in a wide range of 

industrial and consumer applications. 

Epidemiological studies have evaluated 

the associations between PFAS 

exposure and health effects in humans. 

Evidence from these studies in 

occupationally exposed populations, 

residential populations exposed to 

higher levels of PFAS in drinking water, 

and studies in the general population 

suggest associations between PFAS and 

several health outcomes. 

Exposure to PFAS is nearly 

ubiquitous in the United States. 

Epidemiological studies suggest that 

PFAS exposure may impact the immune 

system and susceptibility to viral 

infections. However, there is little 

consistency in the results of studies on 

PFAS exposure and infectious disease. 

The coronavirus disease 2019 (COVID– 

19) pandemic presents a unique concern 

and opportunity to explore this 

association. If PFAS affect the immune 

system, it is possible that they could 

affect susceptibility to infection with 

severe acute respiratory syndrome 

coronavirus 2 (SARS–CoV–2), the virus 

that causes COVID–19, or could affect 

severity of COVID–19 symptoms. 

In 2019 and 2020, the Agency for 

Toxic Substances and Disease Registry 

(ATSDR) conducted statistically based 

biomonitoring PFAS exposure 

assessments (EAs) in eight communities 

that had documented exposures to 

PFAS in drinking water. ATSDR also 

supported two EAs that were designed 

to test the PFAS Exposure Assessment 

Technical Tools (PEATT). PFAS 

concentrations were measured in serum 

collected from EA and PEATT 

assessment participants, and a 

questionnaire was administered to 

gather information to characterize each 

individual’s exposure. These 

communities were investigated under 

‘‘Per- or Polyfluoroalkyl Substances 

Exposure Assessments [PFAS EAs]’’ 

(OMB Control No. 0923–0059, 

expiration date 06/30/2022). During the 

same period, ATSDR initiated a health 

study at the Pease International 

Tradeport that included measurement of 

PFAS serum levels and collection of 

information about individual exposures 

in participants under ‘‘Human Health 

Effects of Drinking Water Exposures to 

Per- and Polyfluoroalkyl Substances 

(PFAS) at Pease International Tradeport, 

Portsmouth, NH (The Pease Study)’’ 

(OMB Control No. 0923–0061, 

expiration date 08/31/2022). 


tkelley on DSK125TN23PROD with NOTICE 
Federal Register / Vol. 87, No. 5 / Friday, January 7, 2022 / Notices 975 

This a new two-year ATSDR 

information collection request (ICR) for 

a collaborative study between the 

Centers for Disease Control and 

Prevention’s National Center for 

Environmental Health (CDC/NCEH) and 

ATSDR. This follow-up study will 

recruit participants who; (1) 

participated in a previous ATSDRfunded study, (2) have existing serumPFAS measurements, and (3) have given 

prior consent for additional contact 

from NCEH/ATSDR. We anticipate that 

the total number of participants enrolled 

in the CDC/ATSDR cohorts will be 

around 3,170 (2,800 adults and 370 

children) individuals. This study will 

attempt to enroll the entire universe of 

eligible participants; therefore, our 

target sample size is 3,170. The cohorts 

have a substantial number of 

participants with high PFAS exposure, 

as well as a sufficient range of serumPFAS concentrations to allow 

examination of associations between the 

outcomes and across a wide range of 

PFAS exposures. 

The objectives are the following: (1) 

To examine the association between 

serum-PFAS collected through the EAs, 

PEATT assessments, and Pease Study 

and the frequency of occurrence of 

selected syndromes (combinations of 

self-reported symptoms), which will be 

used as a proxy for viral infections; and, 

(2) to examine the association between 

serum-PFAS collected through the EAs, 

PEATT assessments, and Pease Study 

and self-reported positive test results 

indicating specific viral infections. 

During the first three months of the 

two-year study period, NCEH/ATSDR 

will invite and consent approximately 

3,170 participants (2,800 adults and 370 

children) to complete a new series of 

surveys to determine whether PFAS 

exposure increases susceptibility to 

viral infections, including, but not 

limited to COVID–19. Data will be 

collected from those who enroll in the 

study through an initial paper-based 

survey and a series of four additional 

surveys over a 12- to 14-month period. 

Follow-up surveys will be offered in 

two modes: Web-based and paper-based. 

It is estimated that 75% of the 

participants will choose the web-based 

mode. Participants will also be given 

symptom diaries to improve recall after 

the initial and between each of the 

follow-up surveys. 

The total time burden requested is 

19,816 hours (or 9,908 hours annually). 

There are no costs to the respondents 

other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Adults ...................................... Initial Questionnaire—Adult (paper) ....................................... 700 1 30/60 

Follow up Questionnaire—Adult (paper) ................................ 175 4 30/60 

Follow up Questionnaire—Adult (REDCap) ........................... 525 4 25/60 

Symptom Diary ....................................................................... 700 1 4 

Children (7–17 years) ............. Initial Questionnaire—Child (paper) ....................................... 70 1 30/60 

Follow up Questionnaire—Child (paper) ................................ 18 4 30/60 

Follow up Questionnaire—Child (REDCap) ........................... 52 4 25/60 

Symptom Diary ....................................................................... 70 1 4 

Parents of Children (3–6 

years).

Initial Questionnaire—Child (paper) ....................................... 12 1 30/60 

Follow up Questionnaire—Child (paper) ................................ 6 4 30/60 

Follow up Questionnaire—Child (REDCap) ........................... 18 4 25/60 

Symptom Diary ....................................................................... 23 1 4 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–00101 Filed 1–6–22; 8:45 am] 

BILLING CODE 4163–70–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Single-Source 

Cooperative Agreement To Fund the 

Kinshasa School of Public Health, 

Democratic Republic of the Congo 

(KSPH, DRC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $700,000, with 

an expected total funding of $3,500,000 

over a five-year period, to the Kinshasa 

School of Public Health, Democratic 

Republic of the Congo (KSPH DRC). The 

award will support the investigation of 

the epidemiological, ecological, and 

anthropological aspects of monkeypox 

and assess clinical intervention 

strategies in the Democratic Republic of 

Congo (DRC). These activities align with 

CDC priorities to promote surveillance 

and global health to prevent the 

international spread of diseases and to 

control them at the source. 

DATES: The period for this award will be 

September 30, 2022, through September 

29, 2027. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Amy Yang, National Center for HIV, 

Viral Hepatitis, STD, and TB Prevention 

(NCHHSTP), Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS US8–1, Atlanta, GA 30329–4027, 

Telephone: 404–718–8835, Email: corp_

erpo_8835@cdc.gov. 

SUPPLEMENTARY INFORMATION: This 

single-source award will support the 

investigation of the epidemiological, 

ecological, and anthropological aspects 

of monkeypox and assess clinical 

intervention strategies in the DRC. 

Research activities will focus on 

improvement and evaluation of labbased surveillance systems, 

investigations of animal reservoirs and 

human behaviors at the human-animal 

interface, epidemiologic investigations, 

genome sequencing and phylogenetic 

analysis, risk mitigation, enhancing 

health communication strategies, and 

clinical evaluation of vaccines and 

therapeutic treatments. The research 

should provide the DRC Ministry of 

Health and other key stakeholders with 

evidence-based strategies to develop 


tkelley on DSK125TN23PROD with NOTICE